Kate Sutherland stared at a tiny cluster of cells glowing red and white under the microscope — a tumor sample from a long-term survivor of small cell lung cancer. What caught her eye wasn’t just the cancer cells, but the rare immune cells weaving through them like hunters in the dark: gamma delta T cells. At the Walter and Eliza Hall Institute (WEHI) in Melbourne, Sutherland and her team had stumbled upon something unseen before — a hidden army within the body capable of recognizing and destroying one of the deadliest cancers on Earth.
Small cell lung cancer kills fast. Fewer than 7 out of every 100 patients survive five years, and immunotherapies that work on other cancers often fail here. The reason? This cancer hides from the immune system so well it’s nearly invisible. But gamma delta T cells, the researchers found, can see through the disguise. In patients with more of these cells in their tumors, survival times were longer — the strongest evidence yet that these rare immune cells are not just present, but actively fighting.
To test their power, the team grew mini tumors in the lab from patient samples collected through the Victorian Cancer Biobank and Royal Melbourne Hospital. When they added gamma delta T cells from the same patients’ blood, the immune cells went to work — hunting down and killing cancer cells. Even more promising: two existing drugs boosted the attack. Zoledronate, commonly used for osteoporosis, increased the number of gamma delta T cells and sharpened their ability to spot tumors. Tarlatamab, already approved for small cell lung cancer, acted like a magnet, pulling the immune cells closer to their target. Together, they supercharged the body’s natural defense.
The discovery opens a new path for treatment — one that doesn’t rely on the usual immune pathways most therapies depend on. For patients who don’t respond to current immunotherapies, this could be life-changing. The team is now exploring adoptive cell therapy, where doctors grow large numbers of a patient’s own gamma delta T cells in the lab and infuse them back, like reinforcements sent to the front lines.
"We've found an immune cell that appears to be able to see through that disguise," said Dr. Jin Ng, the study’s first author. That simple sentence carries the weight of decades of stalled progress. For a disease that has seen few advances, this hidden immune pathway offers real hope — not just for new treatments, but for turning long-term survival from a rarity into a possibility.